Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-03-01
2011-03-01
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387300
Reexamination Certificate
active
07897148
ABSTRACT:
The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
REFERENCES:
patent: 4704366 (1987-11-01), Juarez-Salinas et al.
patent: 4801687 (1989-01-01), Ngo
patent: 4935496 (1990-06-01), Kudo
patent: 4946778 (1990-08-01), Ladner
patent: 5502167 (1996-03-01), Waldmann
patent: 5530101 (1996-06-01), Queen et al.
patent: 5536814 (1996-07-01), Ruoslahti
patent: 5558864 (1996-09-01), Bendig
patent: 5639641 (1997-06-01), Pedersen
patent: 5677181 (1997-10-01), Parish
patent: 5693493 (1997-12-01), Robinson
patent: 5698417 (1997-12-01), Robinson
patent: 5705154 (1998-01-01), Dalie
patent: 5720172 (1998-02-01), Ishizaki
patent: 5750078 (1998-05-01), Shitara
patent: 5770403 (1998-06-01), Dalie et al.
patent: 5874081 (1999-02-01), Parish
patent: 5922676 (1999-07-01), Pasqualini
patent: 5966942 (1999-10-01), Mitchell
patent: 5966943 (1999-10-01), Mitchell
patent: 6094921 (2000-08-01), Zhu et al.
patent: 6123941 (2000-09-01), Bissell et al.
patent: 6256998 (2001-07-01), Gao
patent: 6351954 (2002-03-01), Nogawa et al.
patent: 6852318 (2005-02-01), Varner
patent: 7276589 (2007-10-01), Ramakrishnan et al.
patent: 2002/0172675 (2002-11-01), Varner
patent: 2003/0157641 (2003-08-01), Reff et al.
patent: 2004/0077544 (2004-04-01), Varner
patent: 2004/0259152 (2004-12-01), Murray et al.
patent: 2005/0163769 (2005-07-01), Ramakrishnan et al.
patent: 0 896 002 (1999-02-01), None
patent: 03796541.5 (2007-08-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 95/14772 (1995-06-01), None
patent: WO 95/22618 (1995-08-01), None
patent: WO 97 33887 (1997-09-01), None
patent: WO 99/55913 (1999-11-01), None
patent: WO 99/58139 (1999-11-01), None
patent: WO 01/11086 (2001-02-01), None
patent: WO 01/53262 (2001-07-01), None
patent: WO 01/53297 (2001-07-01), None
patent: WO 02/079492 (2002-10-01), None
patent: PCT/US2004/010422 (2005-02-01), None
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).
De Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. (2002) J. Mol. Biol. 320, 415-428.
Holm et al (2007) Mol. Immunol. 44: 1075-1084.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Dufner (Trends Biotechnol. 24(11):523-29 (2006)).
Pharmigen data sheet for IIA1 antibody (p. 1-2; Oct. 15, 2009).
Pharmigen data sheet for VC5 antibody (p. 1-2; Oct. 15, 2009).
Ryan, S.J.,“The Development of an Experimental Model of Subretinal Neovascularization in Disciform Macular Degeneration”,Transactions of the American Ophthalmological Society, vol. 77 (1979), pp. 707-745.
Ryan, S.J., “Subretinal Neovascularization: Natural History of an Experimental Model”,Archives of Ophthalmology, vol. 100 (1982), pp. 1804-1809.
Rudikoff et al., P.N.A.S. USA, vol. 79 (1982), pp. 1979-1983.
Pytela et al., Cell, vol. 40 (1985), pp. 191-198.
Thorpe et al., “Monoclonal Antibodies in Biological Clinical Applications”, (1985), pp. 475-506.
Argraves et al.,J. Biol. Chem.,vol. 261(28) (1986), pp. 12922-12924.
Amit, et. al.,Science,vol. 233 (1986), pp. 747-753.
Conforti, et al., “Human Endothelial Cells Express Integrin Receptors on the Luminal Aspect of their Membrane”,Blood,vol. 80 (2) (1992), pp. 437-446.
Grossniklaus, Hans et. al., “Immunohistochemical and Histochemcial Properties of Surgically Excised Subretinal Neovascular Membranes in Age-Related Macular Degeneration”,American Journal of Ophthalmology,vol. 114(4) (1992), pp. 464-472.
Hackett, R., et al., (1996) Dermatotoxicology. 5thEdition. (Ed. By F.B. Marzulli and H.I. Maibach) Hemisphere Publishing Corp., Washington, D.C.
Varner et al., “Integrins and Cancer”,Current Opinion in Cell Biology, vol. 8(5) (1996), pp. 724-730.
Varner et al., “Tumor Angiogenesis and the Role of Vascular Cell Integrin Alphavbeta3,”Important Advances in Oncology,(1996), pp. 69-87.
Varner et al., “Antagonists of Vascular Cell Integrin Alpha 5 beta 1 Inhibit Angiogenesis”,Circulation, vol. 98(17) (1998), pp. 4166.
Van Der Loo Johannes C.M. et.al., “VLA-5 is Expressed by Mouse and Human Long-Term Repopulating Hematopoietic Cells and Mediates Adhesion to Extracellular Matrix Protein Fibronectin”,Journal of Clinical Investigation,vol. 102 (5) (1998), pp. 1051-1061.
Storgard, Chris M. et al., “Decreased Angiogenesis and Arthritic Disease in rabbits Treated with an αvβ3 Antagonist”,The Journal of clinical Investigation, vol. 103 (1999), pp. 47-54.
Wu, H., et. al., “The Expression of Integrin Alph5beta1 and Transforming Growth Factor-Beta in Pulmonary Fibrosis of Rat”,Chinese Journal of Pathology,vol. 28(6): abstract (1999).
Wu, et. al.,J. Mol. Biol.,vol. 294 (1999), pp. 151-162.
Zhao, Ming Wei et. al., “A Distinct Integrin-Mediated Phagocytic Pathway for Extracellular Matrix Remodeling by RPE Cells”,Invest. Ophthalmol. Vis. Sci.,vol. 40(11) (1999), pp. 2713-2723.
Tolentino, M.J., et al., “Angiography of Fluoresceinated Anti-Vascular Endothelial Growth Factor Antibody and Dextrans in Experimental Choroidal Neovascularization”,Archives of Ophthalmology,vol. 118 (2000), pp. 78-84.
Edelman and Castro, “Quantitative Image Analysis of Laser-Induced Choroidal Neovascularization in Rat,”Exp. Eye Res,vol. 71 (2000), pp. 523-533.
Kim, Semi et.al., “Regulation of Integrin Alpha5beta3-Mediated Endothelial Cell Migration and Angiogenesis by Integrin Alpha5betal and Protein Kinase”,A Journal of Biological Chemistry,vol. 275(43) (2000), pp. 33920-33928.
Kim, S. et.al., “Regulation of Angiogenesis in Vivo by Ligation of Integrin Alpha5beta1 with the Central Cell-Binding Domain of Fibronectin”,American Journal of Pathology,vol. 156 (4) (2000), pp. 2000-2004.
Loike, J.D. et. al., “Blockade of Alpa 5 Beta 1 Integrins Reverses the Inhibitory Effect of Tenacin on Chemotaxis of Human Monocytes and Polymorphonuclear Leukocytes Through Three-Dimensional Gels of Extracellular Matrix Proteins”,Journal of Immunology,vol. 166(12) (2001), pp. 7534-7542.
Wong, et. al.,Current Eye Research,vol. 22(2) (2001), pp. 140-147.
Zhao, et. al.,J. Cell Biol.,vol. 152 (9) (2001), pp. 65-71.
Josic, D. et.al., “Analytical and Preparative Methods for Purification of Antibodies”,Food Technology and Biotechnology,vol. 39 (3) (2001), pp. 215-226.
Vajdos, et. al.,J. Molec. Biol.,vol. 320 (2002), pp. 415-428.
“Eos Biotechnology Files Investigational New Drug for Novel Targets with Anti-Angiogenic Properties”, www.pharmabiz.com/article/detnews.asp?articleid=13491§ionid=14&z=y>, (2002).
“Protein Design Labs to Acquire Eos Biotechnology”, www.pharmabiz.com/article/detnews.asp?articleid=14199§ionid=14&z=y>, (2003).
Wilson, Sylvia et. al.,. “Fibronectin Fragments Promote Human Retinal Endothelial Cell Adhesion and Proliferation and ERK Activation Through Alph5beta1 Integrin and PI 3-Kinase”,Invest. Ophthalmol. Vis. Sci.,vol. 44(4) (2003), pp. 1704-1715.
Proulx et al., “Effect of Quiescence on Integrin ÿÿ Expression in Human Retinal Pigment Epithelium”,Molecular Vision,vol. 9 (2003), pp. 473-481.
Ramakrishnan Vanitha et.al., “A Function-Blocking Chimeric Antibody Eos200-4, Against Alpha5beta1 Integrin Inhibits Angiogenesis in a Monkey Model”,Proceedings of the American Association for Cancer Research Ann
Bhaskar Vinay
Jeffry Ursula
Johnson Dale E.
Powers David
Ramakrishnan Vanitha
Abbott Biotherapeutics Corp.
Bristol Lynn
Sughrue & Mion, PLLC
LandOfFree
Chimeric and humanized antibodies to α5β1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric and humanized antibodies to α5β1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric and humanized antibodies to α5β1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675198